Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tapentadol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 3/20 | 1.00 |
| ▸ | SLC6A2 known ✓ | P23975 | 6/20 | 0.38 |
| ▸ | SLC22A1 | O15245 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.42 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.42 |
| ▸ | HTR2A | P28223 | 2/20 | 0.42 |
| ▸ | MIF | P14174 | 1/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | GALR3 | O60755 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.41 |
| ▸ | DRD1 | P21728 | 2/20 | 0.41 |
| ▸ | DRD3 | P35462 | 2/20 | 0.41 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tapentadol SCHEMBL29447436 | 1.00 | OPRM1 (1.00) | OPRM1SLC22A1ADRA1AADRB1HTR2A | |
| Tapentadol SCHEMBL146800 | 1.00 | OPRM1 (1.00) | OPRM1SLC22A1ADRA1AADRB1HTR2A | |
| Tapentadol SCHEMBL1425181 | 1.00 | OPRM1 (1.00) | OPRM1SLC22A1ADRA1AADRB1HTR2A | |
| Tapentadol SCHEMBL116924 | 1.00 | OPRM1 (1.00) | OPRM1SLC22A1ADRA1AADRB1HTR2A | |
| Tapentadol SCHEMBL16267561 | 1.00 | OPRM1 (1.00) | OPRM1SLC22A1ADRA1AADRB1HTR2A | |
| Tapentadol SCHEMBL147058 | 1.00 | OPRM1 (1.00) | OPRM1SLC22A1ADRA1AADRB1HTR2A | |
| Tapentadol SCHEMBL16266162 | 1.00 | OPRM1 (1.00) | OPRM1SLC22A1ADRA1AADRB1HTR2A | |
| Tapentadol SCHEMBL416917 | 1.00 | OPRM1 (1.00) | OPRM1SLC22A1ADRA1AADRB1HTR2A | |
| Tapentadol SCHEMBL16267909 | 1.00 | OPRM1 (1.00) | OPRM1SLC22A1ADRA1AADRB1HTR2A | |
| Tapentadol SCHEMBL29611116 | 1.00 | OPRM1 (1.00) | OPRM1SLC22A1ADRA1AADRB1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140356314-A1 | 3-[3-(DIMETHYLAMINO)-1-ETHYL-2-METHYLPROPYL]PHENOL RESIN COMPLEX | AREVIPHARMA GMBH (DE) | 2014-12-04 | — | — | US | claimed |
| US-11739049-B2 | Process for the preparation of (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol | Grünenthal GmbH (DE) | 2023-08-29 | — | — | US | disclosed |
| US-20220177413-A1 | PROCESS FOR THE PREPARATION OF TAPENTADOL AND ANALOGS THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2022-06-09 | — | — | US | disclosed |
| US-20170233330-A1 | Process for the preparation of 3-[(1R,2R)-3-(Dimethylamino)-1-ethyl-2-methylpropyl]-phenol | SANDOZ AG (CH) | 2017-08-17 | — | — | US | disclosed |
| EP-2507203-B1 | NEW PROCESS FOR THE PREPARATION OF TAPENTADOL AND INTERMEDIATES THEREOF | EUTICALS SPA (IT) | 2017-07-05 | — | — | EP | disclosed |
| US-9670200-B2 | Quaternary ammonium salt prodrugs | ALKERMES PHARMA IRELAND LIMITED (IE) | 2017-06-06 | — | — | US | disclosed |
| EP-2792668-B1 | Process for the preparation of substituted 3-(1-amino-2-methyl-pentane-3-yl)phenyl compounds | GRUENENTHAL GMBH (DE) | 2017-05-31 | — | — | EP | disclosed |
| EP-2519100-B1 | INTERMEDIATE COMPOUNDS AND PROCESSES FOR THE PREPARATION OF TAPENTADOL AND RELATED COMPOUNDS | MAPI PHARMA LTD (IL) | 2017-03-15 | — | — | EP | disclosed |
| US-20160361276-A1 | Pharmaceutical Combination | GRUENENTHAL GMBH (DE) | 2016-12-15 | — | — | US | disclosed |
| EP-2992877-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF PAIN | Grünenthal GmbH (DE) | 2016-03-09 | — | — | EP | disclosed |
| US-20120232306-A1 | PROCESS FOR THE PREPARATION OF TAPENTADOL AND INTERMEDIATES THEREOF | EUTICALS S.P.A. (IT) | 2012-09-13 | — | — | US | disclosed |
| WO-2012001571-A1 | NEW PROCESS FOR THE SYNTHESIS OF TAPENTADOL AND INTERMEDIATES THEREOF | ARCHIMICA SRL (IT) | 2012-01-05 | — | — | WO | disclosed |
| WO-2011080756-A1 | PROCESS FOR THE PREPARATION OF 1-PHENYL-3-DIMETHYLAMINOPROPANE DERIVATIVES | IND-SWIFT LABORATORIES LIMITED (IN) | 2011-07-07 | — | — | WO | disclosed |
| WO-2011080736-A1 | INTERMEDIATE COMPOUNDS AND PROCESSES FOR THE PREPARATION OF TAPENTADOL AND RELATED COMPOUNDS | MAPI PHARMA HK LIMITED (CN) | 2011-07-07 | — | — | WO | disclosed |
| WO-2011067714-A1 | NEW PROCESS FOR THE PREPARATION OF TAPENTADOL AND INTERMEDIATES THEREOF | ARCHIMICA SRL (IT) | 2011-06-09 | — | — | WO | disclosed |
| EP-1699440-B1 | METHOD FOR THE PRODUCTION OF AN ADMINISTRATION FORM WHICH IS SECURED AGAINST MISUSE | GRUENENTHAL GMBH (DE) | 2009-11-11 | — | — | EP | disclosed |
| US-20090099138-A1 | NSAIDs and tapentadol; synergistic pain relief | GRUENENTHAL GMBH (DE) | 2009-04-16 | — | — | US | disclosed |
| EP-2012763-A1 | PHARMACEUTICAL COMBINATION COMPRISING 3- (3-DIMETHYLAMIN0-1-ETHYL-2-METHYL-PR0PYL) -PHENOL AND AN NSAID | Grünenthal GmbH (DE) | 2009-01-14 | — | — | EP | disclosed |
| WO-2007128412-A1 | PHARMACEUTICAL COMBINATION COMPRISING 3- (3-DIMETHYLAMIN0-1-ETHYL-2-METHYL-PR0PYL) -PHENOL AND AN NSAID | Grünenthal GmbH (DE) | 2007-11-15 | — | — | WO | disclosed |
| EP-1612203-B1 | Crystalline forms of (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride | GRUENENTHAL GMBH (DE) | 2007-08-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232306-A1 | PROCESS FOR THE PREPARATION OF TAPENTADOL AND INTERMEDIATES THEREOF | OPRK1, OPRD1, OPRL1 | OPRM1 4/4885SLC6A2 282/4885SLC22A1 3207/4885 |
| US-20160361276-A1 | Pharmaceutical Combination | MC2R, PTGER2, PTGER1 | OPRM1 21/4885SLC6A2 743/4885SLC22A1 2078/4885 |
| US-20170233330-A1 | Process for the preparation of 3-[(1R,2R)-3-(Dimethylamino)-1-ethyl-2-methylpropyl]-phenol | AGTR1, SAT1, TMT1A | OPRM1 1153/4885SLC6A2 1382/4885SLC22A1 1704/4885 |
| US-11739049-B2 | Process for the preparation of (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol | COMT, CYP1A1, CYP2E1 | OPRM1 201/4885SLC6A2 3218/4885SLC22A1 4825/4885 |
| US-20220177413-A1 | PROCESS FOR THE PREPARATION OF TAPENTADOL AND ANALOGS THEREOF | CYP1A1, CYP1B1, OPRL1 | OPRM1 11/4885SLC6A2 310/4885SLC22A1 1725/4885 |
| US-20090099138-A1 | NSAIDs and tapentadol; synergistic pain relief | PTGS1, OPRL1, PTGES3 | OPRM1 29/4885SLC6A2 96/4885SLC22A1 1301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.